369 related articles for article (PubMed ID: 27477617)
1. Comparison of three preclinical models for nausea and vomiting assessment.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
[TBL] [Abstract][Full Text] [Related]
2. Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron.
Goineau S; Guillaume P; Barrais L; Castagné V
Fundam Clin Pharmacol; 2014 Dec; 28(6):643-51. PubMed ID: 24750138
[TBL] [Abstract][Full Text] [Related]
3. Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats.
Takeda N; Hasegawa S; Morita M; Horii A; Uno A; Yamatodani A; Matsunaga T
Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):647-52. PubMed ID: 9053584
[TBL] [Abstract][Full Text] [Related]
4. Pica in rats is analogous to emesis: an animal model in emesis research.
Takeda N; Hasegawa S; Morita M; Matsunaga T
Pharmacol Biochem Behav; 1993 Aug; 45(4):817-21. PubMed ID: 8415820
[TBL] [Abstract][Full Text] [Related]
5. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
6. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
7. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
[TBL] [Abstract][Full Text] [Related]
8. Differential action of domperidone to modify emesis and behaviour induced by apomorphine in the ferret.
Lau AH; Ngan MP; Rudd JA; Yew DT
Eur J Pharmacol; 2005 Jun; 516(3):247-52. PubMed ID: 15963978
[TBL] [Abstract][Full Text] [Related]
9. Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats.
Takeda N; Hasegawa S; Morita M; Horii A; Uno A; Yamatodani A; Matsunaga T
Methods Find Exp Clin Pharmacol; 1995 Nov; 17(9):589-90. PubMed ID: 8786672
[TBL] [Abstract][Full Text] [Related]
10. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
Yoshida N; Omoya H; Ito T
J Pharmacol Exp Ther; 1992 Mar; 260(3):1159-65. PubMed ID: 1532032
[TBL] [Abstract][Full Text] [Related]
11. Diphenidol has no actual broad antiemetic activity in dogs and ferrets.
Nakayama H; Yamakuni H; Nakayama A; Maeda Y; Imazumi K; Matsuo M; Mutoh S
J Pharmacol Sci; 2004 Nov; 96(3):301-6. PubMed ID: 15528840
[TBL] [Abstract][Full Text] [Related]
12. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.
Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA
Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289
[TBL] [Abstract][Full Text] [Related]
13. Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets.
Yamakuni H; Sawai-Nakayama H; Imazumi K; Maeda Y; Matsuo M; Manda T; Mutoh S
Eur J Pharmacol; 2002 May; 442(3):273-8. PubMed ID: 12065081
[TBL] [Abstract][Full Text] [Related]
14. Strain differences in the development of cisplatin-induced pica behavior in mice.
Yamamoto K; Yamatodani A
J Pharmacol Toxicol Methods; 2018; 91():66-71. PubMed ID: 29407728
[TBL] [Abstract][Full Text] [Related]
15. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
16. Scutellaria baicalensis extract decreases cisplatin-induced pica in rats.
Aung HH; Dey L; Mehendale S; Xie JT; Wu JA; Yuan CS
Cancer Chemother Pharmacol; 2003 Dec; 52(6):453-8. PubMed ID: 12942313
[TBL] [Abstract][Full Text] [Related]
17. [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Galy G; Labidi SI; Tissier F; Combes JD; Auger A; Favier B; Latour JF
Bull Cancer; 2009 Feb; 96(2):141-5. PubMed ID: 19258220
[TBL] [Abstract][Full Text] [Related]
18. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
19. Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret.
Sam TS; Kan KK; Ngan MP; Rudd JA; Yeung JH
Eur J Pharmacol; 2003 Apr; 466(1-2):163-8. PubMed ID: 12679153
[TBL] [Abstract][Full Text] [Related]
20. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
